| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD007287.PUB4 |
| P698 | PubMed publication ID | 30199097 |
| P50 | author | Toos Daemen | Q61111896 |
| P2093 | author name string | Ben J Cohlen | |
| H Marike Boezen | |||
| Hans W Nijman | |||
| Ninke Leffers | |||
| Wijnand Helfrich | |||
| Marco de Bruyn | |||
| Cornelis Jm Melief | |||
| Cornelis JM Melief | |||
| Sterre T Paijens | |||
| P2860 | cites work | WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report | Q84843975 |
| Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care | Q87120295 | ||
| Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors | Q87216241 | ||
| Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients | Q87769925 | ||
| Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial | Q88126552 | ||
| Immunotherapy in ovarian cancer | Q89613960 | ||
| Antigen-specific active immunotherapy for ovarian cancer | Q24193567 | ||
| Antigen-specific active immunotherapy for ovarian cancer | Q24240962 | ||
| Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report | Q24615762 | ||
| The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial | Q24629295 | ||
| What is "quality of evidence" and why is it important to clinicians? | Q24647929 | ||
| A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu | Q24649530 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Evaluating non-randomised intervention studies | Q29619272 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer | Q30445914 | ||
| Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial | Q31047715 | ||
| A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside | Q33724878 | ||
| Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation | Q33887648 | ||
| Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer | Q33932032 | ||
| The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer | Q33939202 | ||
| Chemotherapy for advanced ovarian cancer: overview of randomized trials | Q34010421 | ||
| Monoclonal antibodies and idiotypic network activation for ovarian carcinoma | Q72208056 | ||
| Antitumor antibodies for immunotherapy of ovarian carcinomas | Q72754410 | ||
| Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides | Q73226772 | ||
| Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer | Q73670440 | ||
| Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization | Q73707371 | ||
| Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor ant | Q73877514 | ||
| Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine | Q73934556 | ||
| Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity | Q74079764 | ||
| Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines | Q74211468 | ||
| Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo | Q74260446 | ||
| Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients | Q74546921 | ||
| Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study | Q74813455 | ||
| Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers | Q77869898 | ||
| Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine | Q77948431 | ||
| Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival | Q78167058 | ||
| The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR | Q79149161 | ||
| Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers | Q79367870 | ||
| Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer | Q80233809 | ||
| CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients | Q80422206 | ||
| Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients | Q80547528 | ||
| Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma | Q81377645 | ||
| A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer | Q81604925 | ||
| Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome | Q81897940 | ||
| Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy | Q82330719 | ||
| [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers] | Q83170202 | ||
| Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer | Q83427971 | ||
| Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group | Q84512650 | ||
| Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease | Q84573870 | ||
| LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. | Q34111719 | ||
| The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis | Q34188723 | ||
| Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 | ||
| Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. | Q34492778 | ||
| Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. | Q35039508 | ||
| Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients | Q35116211 | ||
| Immunotherapy for ovarian cancer. | Q35164189 | ||
| CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 | ||
| FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication | Q35419216 | ||
| A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer | Q35582228 | ||
| A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction | Q35787391 | ||
| Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients | Q35889432 | ||
| Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer | Q35921697 | ||
| Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells | Q35995520 | ||
| Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients | Q36011425 | ||
| Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial | Q36302848 | ||
| First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients | Q36341084 | ||
| Novel therapeutic agents in ovarian cancer | Q36480642 | ||
| A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. | Q36544827 | ||
| Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase | Q36642248 | ||
| A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission | Q36841027 | ||
| A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients | Q37002959 | ||
| Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial | Q37024702 | ||
| Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis | Q37102182 | ||
| Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma | Q37169042 | ||
| Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement | Q37193049 | ||
| Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors | Q37412304 | ||
| Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma | Q37477273 | ||
| Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer | Q37585487 | ||
| Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients | Q37716642 | ||
| Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine | Q38680054 | ||
| New Approaches for Immune Directed Treatment for Ovarian Cancer | Q38760516 | ||
| Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells | Q39001295 | ||
| MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer | Q39596466 | ||
| Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. | Q39720586 | ||
| Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival | Q39804019 | ||
| Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer | Q40019095 | ||
| NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. | Q40064053 | ||
| Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer | Q40444431 | ||
| Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. | Q40469093 | ||
| A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer | Q40512575 | ||
| Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells | Q40741896 | ||
| Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial | Q40872664 | ||
| Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine | Q40977063 | ||
| Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. | Q40995818 | ||
| Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy | Q42093293 | ||
| The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays | Q42859721 | ||
| Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study | Q43793343 | ||
| Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial | Q43886638 | ||
| A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen | Q44423662 | ||
| Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial | Q44426842 | ||
| Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. | Q44520892 | ||
| CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer | Q44772343 | ||
| Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino | Q45197611 | ||
| Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes | Q45883836 | ||
| Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer | Q46187608 | ||
| Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. | Q46616110 | ||
| Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study | Q46920170 | ||
| Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine | Q47605465 | ||
| Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). | Q47815717 | ||
| Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). | Q47936662 | ||
| Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). | Q47969162 | ||
| Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission | Q47993135 | ||
| Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. | Q50457532 | ||
| The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. | Q51754017 | ||
| Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. | Q51792057 | ||
| Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. | Q51982834 | ||
| Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. | Q52009428 | ||
| NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. | Q53257187 | ||
| Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. | Q54275386 | ||
| Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response. | Q55044203 | ||
| Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients | Q57975533 | ||
| HER2 Dendritic Cell Vaccines | Q58409705 | ||
| Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer | Q64378051 | ||
| Active Immunization of Human Ovarian Cancer Patients Against a Common Carcinoma (Thomsen-Friedenreich) Determinant Using a Synthetic Carbohydrate Antigen | Q68145704 | ||
| Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy | Q71254387 | ||
| Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine | Q71659957 | ||
| CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy | Q71694390 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | CD007287 | |
| P577 | publication date | 2018-09-10 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Antigen-specific active immunotherapy for ovarian cancer | |
| P478 | volume | 9 |
Search more.